S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

National Research Stock Forecast, Price & News

-0.60 (-1.48%)
(As of 11/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
99,782 shs
Average Volume
31,693 shs
Market Capitalization
$1.02 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NRC News and Ratings via Email

Sign-up to receive the latest news and ratings for National Research and its competitors with MarketBeat's FREE daily newsletter.

National Research logo

About National Research

National Research Corp. engages in the provision of analytics and insights that facilitate patient, employee, and customer retention. It offers solutions that address specific needs around market insight, experience, transparency, and governance for healthcare providers, payers, and other healthcare organizations. The company was founded by Michael D. Hays in 1981 and is headquartered in Lincoln, NE.


See More Headlines

Industry, Sector and Symbol

Commercial physical research
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$133.28 million
Cash Flow
$1.46 per share
Book Value
$3.27 per share


Net Income
$37.26 million
Pretax Margin




Free Float
Market Cap
$1.02 billion
Not Optionable

Company Calendar

Dividend Payable
Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.49 out of 5 stars

Business Services Sector

294th out of 423 stocks

Commercial Physical Research Industry

20th out of 27 stocks

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

National Research (NASDAQ:NRC) Frequently Asked Questions

How has National Research's stock price been impacted by Coronavirus (COVID-19)?

National Research's stock was trading at $52.18 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NRC stock has decreased by 23.2% and is now trading at $40.05.
View which stocks have been most impacted by COVID-19

When is National Research's next earnings date?

National Research is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for National Research

How were National Research's earnings last quarter?

National Research Co. (NASDAQ:NRC) released its earnings results on Tuesday, November, 2nd. The company reported $0.38 EPS for the quarter. The business earned $37.77 million during the quarter. National Research had a net margin of 24.96% and a trailing twelve-month return on equity of 48.54%.
View National Research's earnings history

How often does National Research pay dividends? What is the dividend yield for National Research?

National Research announced a quarterly dividend on Friday, November 19th. Shareholders of record on Thursday, December 30th will be paid a dividend of $0.12 per share on Friday, January 14th. This represents a $0.48 annualized dividend and a yield of 1.20%. The ex-dividend date of this dividend is Wednesday, December 29th.
View National Research's dividend history

Is National Research a good dividend stock?

National Research pays an annual dividend of $0.48 per share and currently has a dividend yield of 1.18%. National Research does not yet have a strong track record of dividend growth. The dividend payout ratio of National Research is 34.04%. This payout ratio is at a healthy, sustainable level, below 75%.
View National Research's dividend history.

Who are National Research's key executives?

National Research's management team includes the following people:
  • Michael D. Hays, President, Chief Executive Officer & Director
  • Jona S. Raasch, Chief Operating Officer
  • Kevin R. Karas, CFO, Secretary, Treasurer & Senior Vice President
  • Helen L Hrdy, Chief Growth Officer

What is Michael D. Hays' approval rating as National Research's CEO?

85 employees have rated National Research CEO Michael D. Hays on Glassdoor.com. Michael D. Hays has an approval rating of 87% among National Research's employees.

What other stocks do shareholders of National Research own?

Based on aggregate information from My MarketBeat watchlists, some companies that other National Research investors own include Altria Group (MO), Enterprise Products Partners (EPD), AbbVie (ABBV), Dominion Energy (D), Gilead Sciences (GILD), Pfizer (PFE), Toronto-Dominion Bank (TD), Verizon Communications (VZ), Wells Fargo & Company (WFC) and TD Ameritrade (AMTD).

What is National Research's stock symbol?

National Research trades on the NASDAQ under the ticker symbol "NRC."

Who are National Research's major shareholders?

National Research's stock is owned by many different institutional and retail investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (13.12%), Neuberger Berman Group LLC (3.82%), BlackRock Inc. (3.52%), Conestoga Capital Advisors LLC (2.57%), Dimensional Fund Advisors LP (2.53%) and Renaissance Technologies LLC (1.74%). Company insiders that own National Research stock include Amandla Mk Trust, Joann M Martin, John N Nunnelly, Kevin R Karas and Steven D Jackson.
View institutional ownership trends for National Research

Which major investors are selling National Research stock?

NRC stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Conestoga Capital Advisors LLC, BlackRock Inc., Neuberger Berman Group LLC, Renaissance Technologies LLC, Janus Henderson Group PLC, US Bancorp DE, and Morgan Stanley. Company insiders that have sold National Research company stock in the last year include Amandla Mk Trust, and Joann M Martin.
View insider buying and selling activity for National Research
or view top insider-selling stocks.

Which major investors are buying National Research stock?

NRC stock was purchased by a variety of institutional investors in the last quarter, including Mawer Investment Management Ltd., Martingale Asset Management L P, Daiwa Securities Group Inc., Willis Investment Counsel, Seizert Capital Partners LLC, Kayne Anderson Rudnick Investment Management LLC, SG Americas Securities LLC, and Barclays PLC.
View insider buying and selling activity for National Research
or or view top insider-buying stocks.

How do I buy shares of National Research?

Shares of NRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is National Research's stock price today?

One share of NRC stock can currently be purchased for approximately $40.05.

How much money does National Research make?

National Research has a market capitalization of $1.02 billion and generates $133.28 million in revenue each year. The company earns $37.26 million in net income (profit) each year or $1.41 on an earnings per share basis.

How many employees does National Research have?

National Research employs 485 workers across the globe.

What is National Research's official website?

The official website for National Research is www.nrchealth.com.

Where are National Research's headquarters?

National Research is headquartered at 1245 Q STREET, LINCOLN NE, 68508.

How can I contact National Research?

National Research's mailing address is 1245 Q STREET, LINCOLN NE, 68508. The company can be reached via phone at (402) 475-2525 or via fax at 402-475-9061.

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.